To determine whether PRSS2 has clinical relevance as a potential therapeutic target, we evaluated its expression by immunohistochemistry in series of human breast and prostate cancers (Fig. 4A, B and Supplementary Fig. S7). This evidence concerns the gene PRSS2 and prostate carcinoma.